Addendum: Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders. Int. J. Mol. Sci. 2010, 11, 2566–2575
2.15. Niacinamide (Obtained by Procter & Gamble Company in 2007)
References
- Ando, H; Matsui, MS; Ichihashi, M. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int. J. Mol. Sci 2010, 11, 2566–2575. [Google Scholar]
- Shalita, AR; Smith, JG; Parish, LH; Sofman, MS; Chalker, DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol 1995, 34, 434–437. [Google Scholar]
- Hakozaki, T; Minwalla, L; Zhuang, J; Chhoa, M; Matsubara, A; Miyamoto, K; Greatens, A; Hillebrand, GG; Bissett, DL; Boissy, RE. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol 2002, 147, 20–31. [Google Scholar]
- Greatens, A; Hakozaki, T; Koshoffer, A; Epstein, H; Schwemberger, S; Babcock, G; Bissett, D; Takiwaki, H; Arase, S; Wickett, RR; Boissy, RE. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp. Dermatol 2005, 14, 498–508. [Google Scholar]
Target | Mechanism | Detail | Skin Lightening QD | ||
---|---|---|---|---|---|
Melanocyte | Inhibition of tyrosinase activity | Anti-oxidation | Ascorbic acid/derivatives | ||
Chelating copper atoms | Kojic acid | Ellagic acid | |||
Competitive inhibition | Arbutin 4MSK | Rucinol® 4-HPB | |||
Decrease of tyrosinase protein level | Acceleration of Tyr degradation | Linoleic acid | |||
Inhibition of Tyr maturation | Magnolignan® | ||||
Keratinocyte | Inhibition of KC-MC signaling | Inhibition of UV inflammation | Chamomilla extract Tranexamic acid/derivative | ||
Melanocyte and Keratinocyte | Inhibition of melanosome transfer | Inhibition of melanin dispersion | Niacinamide | ||
Epidermis | Acceleration of epidermal turnover | Desquamation of melanin | Placental extract Adenosine mono-phosphate |
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Ando, H.; Matsui, M.S.; Ichihashi, M. Addendum: Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders. Int. J. Mol. Sci. 2010, 11, 2566–2575. Int. J. Mol. Sci. 2010, 11, 2699-2700. https://doi.org/10.3390/ijms11072699
Ando H, Matsui MS, Ichihashi M. Addendum: Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders. Int. J. Mol. Sci. 2010, 11, 2566–2575. International Journal of Molecular Sciences. 2010; 11(7):2699-2700. https://doi.org/10.3390/ijms11072699
Chicago/Turabian StyleAndo, Hideya, Mary S. Matsui, and Masamitsu Ichihashi. 2010. "Addendum: Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders. Int. J. Mol. Sci. 2010, 11, 2566–2575" International Journal of Molecular Sciences 11, no. 7: 2699-2700. https://doi.org/10.3390/ijms11072699